Loading
Every dated change on the records linked to High-risk neuroblastoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2
No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added.
ORR 63%, CR 33%; 3-year OS 60%.
EFS HR 0.
A milestone in how this cancer is treated.
Relapsed/refractory high-risk neuroblastoma in bone or bone marrow with partial response, minor response or stable disease, with GM-CSF (accelerated)
ORR 50%.
A milestone in how this cancer is treated.
Dinutuximab beta: high-risk neuroblastoma after induction/transplant; relapsed/refractory disease
Objective response 52.
BuMel > CEM (EFS 50% vs 38%); IL-2 adds no benefit to anti-GD2.
A milestone in how this cancer is treated.
High-risk neuroblastoma after at least partial response to induction, with GM-CSF, IL-2 and isotretinoin
A milestone in how this cancer is treated.